StreetAlpha.app
Home › Stocks › SUPN

Supernus, Inc. (SUPN)

Healthcare
$28.61
▲ +0.92%
LAST CLOSE · NOV 20

Supernus is a Rockville, Maryland pharmaceutical company that sells prescription medicines to patients through healthcare providers. It last closed at $28.61 on Nov 20, up 0.92% on the day. The next earnings report for SUPN is expected around Thu, Feb 11, 2027, after the close. For the quarter ended Sep 2026, SUPN reported EPS of $1.12 on revenue of $356.0M, with revenue up 13.4% from a year ago. Over its last 8 reports the stock moved an average of 1.2% the session after earnings. Over the last 12 months SUPN insiders bought $312K of stock on the open market and sold $13.1M, according to SEC Form 4 filings.

AI Auto Pilots
Is SUPN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold SUPN.

Key Stats

Last 12 months
Results
Revenue
$1.4B
+16.4% vs a year ago
Net income
$450.0M
+248.8% vs a year ago
EPS (diluted)
$3.57
+253.5% vs a year ago
Free cash flow
$31.0M
2.3% margin
Valuation
Market cap
$3.4B
118.0M shares
P/E
8.0
Price over 12 month EPS
Price to sales
2.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$305.0M
At Sep 30
Debt
$488.0M
At Sep 30
Shareholder equity
−$60.0M
Buybacks
$302.0M
Last 12 months
Employees1,000 (Jun 30, 2025)
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $791.0M$791.0MFY2021FY2022: $901.0M$901.0MFY2022FY2023: $1.1B$1.1BFY2023FY2024: $1.2B$1.2BFY2024FY2025: $1.2B$1.2BFY2025

From SUPN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 29). Last 12 months adds up the four latest quarters.

Next report
Feb 11
Estimated date · After the close
Reported EPS
$1.12
Quarter ended Sep 2026
Year ago EPS
$0.33
+239.4% on a GAAP basis
Revenue
$356.0M
+13.4% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.16Dec '24Mar 2025: $0.38Mar '25Jun 2025: $0.14Jun '25Sep 2025: $0.33Sep '25Dec 2025: $0.79Dec '25Mar 2026: $0.69Mar '26Jun 2026: $0.98Jun '26Sep 2026: $1.12Sep '26Latest $1.12
Revenue by quarter
Dec 2024: $299.0MDec '24Mar 2025: $266.0MMar '25Jun 2025: $302.0MJun '25Sep 2025: $314.0MSep '25Dec 2025: $358.0MDec '25Mar 2026: $317.0MMar '26Jun 2026: $343.0MJun '26Sep 2026: $356.0MSep '26Latest $356.0M
How SUPN moved after its last 8 reports
Average move the session after a report ±1.2%
Oct 19, 2026After the close+3.5%
Jul 22, 2026After the close+0.5%
Apr 22, 2026After the close+0.2%
Feb 12, 2026After the close+2.0%
Oct 21, 2025After the close0.0%
Jul 22, 2025After the close+0.9%
Apr 23, 2025After the close+1.6%
Feb 11, 2025After the close+0.9%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on SUPNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on SUPN: 0 upgrades, 0 downgrades, 1 initiation
Wells Fargo & CompanyInitiated
Nov 21  

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on SUPN
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on SUPN

Technical Analysis

SUPN · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 13% below its 20 day and 33% below its 50 day average. It is 60% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 32), near oversold. The nearest support is the Pivot S1 at $28.00, and the nearest resistance the Pivot at $28.76.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 6.7%/day
Key levels
$59.6852 week high+108.6%
$45.84200 day average+60.2%
$42.27100 day average+47.7%
$38.1650 day average+33.4%
$32.2520 day average+12.7%
$30.18Swing high (Nov 12)+5.5%
$29.36Pivot R1+2.6%
$28.76Pivot+0.5%
$28.61Last close
$28.00Pivot S1−2.1%
$25.9252 week low−9.4%
$25.92Swing low (Nov 6)−9.4%
Indicators
RSI (14)31.66Weak, oversold below 30Neutral
MACD-3.15Above its signal lineBullish
Stochastic25.8Middle of its rangeNeutral
ADX (14)34.9Trending down
Williams %R-52.8Oversold below −80, overbought above −20Neutral
CCI (20)-44.5Oversold below −100, overbought above 100Neutral
Rate of change+9.4%Change over 10 sessionsBullish
ATR (14)$1.90Typical daily range, 6.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for SUPN

What happened before

See how SUPN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow SUPN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How SUPN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2012.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for SUPNHow many large options trades hit SUPN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

SUPN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bearish
Strongly bearishNeutralStrongly bullish
  • ▼134 buying vs 176 selling
  • ▼Held by funds -2.7 pts
  • ▼Funds holding -39
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding294333−11.7%
In funds' top 1043+33.3%
Held by funds48.4%51.1%−2.7 pts
New / increased31 / 10344 / 119−17.8%
Reduced / sold out107 / 69112 / 35+19.7%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SUPN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

SUPN Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$312K10 buys · 7 insiders
Sold$13.1M12 sales · 9 insiders
86% of the selling was under pre-arranged trading plans.
Cluster buy: 5 insiders bought $172K between Jan 5 and Jan 5.
2025-12 sold $1.0M2026-01 bought $172K2026-02 sold $228K2026-03 bought $31K2026-03 sold $9.0M2026-06 sold $2.1M2026-07 sold $765K2026-08 bought $108KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 27Woodrow D AndersonChief Accounting OfficerBuy1,500$35.69$54K
Aug 5Woodrow D AndersonChief Accounting OfficerBuy1,500$36.28$54K
Jul 10Christian HeidbrederChief Scientific OfficerSale plan18,586$41.14$765K
Jun 11Christian HeidbrederChief Scientific OfficerSale plan18,586$38.06$707K
Jun 8Ryan PreblickCFOSale plan36,000$37.70$1.4M
Mar 18Padmanabh P. BhattSr. VP of IP, CSOSale plan107,250$50.24$5.4M
Every insider buy and sale for SUPN over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See SUPN insider trades →

From SEC Form 4 filings by SUPN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SUPN is in one of them and how their past SUPN trades turned out.

SUPN in the AI portfolios
Loading…

SUPN News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SUPN in an article yet. Here's the latest on the wider market.

SUPN in the news

SUPN Congress Trades

All congress trades →
Trades, 12 months
2
Buys
2
100%
Sells
0
0%
People
1
Last filed Apr 7
Who traded SUPN · since 2020
Latest 5 filings of 9
$1K – $15KTraded Mar 3, 2026Filed Apr 7, 2026
$1K – $15KTraded Dec 11, 2025Filed Jan 12, 2026
Gilbert CisnerosSell (partial)
$1K – $15KTraded Oct 9, 2025Filed Nov 18, 2025
$1K – $15KTraded Mar 24, 2025Filed Apr 7, 2025
Josh GottheimerSell (partial)
$1K – $15KTraded Dec 23, 2022Filed Jan 13, 2023
PersonTypeAmountTradedFiledDelay
Gilbert CisnerosD · CABuy$1K – $15KMar 3, 2026Apr 7, 202635 d
Gilbert CisnerosD · CABuy$1K – $15KDec 11, 2025Jan 12, 202632 d
Gilbert CisnerosD · CASell (partial)$1K – $15KOct 9, 2025Nov 18, 202540 d
Gilbert CisnerosD · CABuy$1K – $15KMar 24, 2025Apr 7, 202514 d
Josh GottheimerD · NJSell (partial)$1K – $15KDec 23, 2022Jan 13, 202321 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Supernus

Supernus is a pharmaceutical company based in Rockville, Maryland. It develops and sells prescription medicines, which it markets through a sales force that calls on healthcare providers. Patients use these products, and government and private health programs help pay for them. The company sells in the United States and in other countries, and it also conducts research and development to bring new medicines to market.

Headquarters
Rockville, MD